

XDNA

Kelly CRISPR & Gene Editing Technology ETF

Fund Description

XDNA tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology.

FactSet Analyst Report

XDNA provides vanilla exposure to a very niche segment of the healthcare sector. The fund is passively managed, tracking an index of firms listed in developed markets that are involved in the research and development of DNA modification technology and its applications. Eligible companies must meet investability requirements and should derive significant revenue or profit from business activities related to (i) CRISPR & gene editing technology, (ii) gene editing development solutions, and (iii) gene editing sequencing solutions. The index may include common stocks, REITs, depositary receipts, and preferred stocks of large-, mid-, and small-cap companies. The resulting portfolio holds a maximum of 60 constituents, weighted by market capitalization. The index reconstitutes and rebalances its portfolio on a quarterly basis.

